Jump to content

Margo Cohen

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Trappist the monk (talk | contribs) at 14:23, 19 February 2016 (→Research: replace et al. in author/editor parameters with |display-authors=etal or |display-editors=etal; using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Margo P. Cohen
Alma materUniversity of Michigan Medical School and the University of Buenos Aires
Occupation(s)Physician, scientist, professor, endocrinologist, entrepreneur
EmployerGlycadia
Known forDiabetes research
TitlePresident and Chief Scientific Officer
SpousePerry M. Cohen
ChildrenMichael H. Cohen, Daniel A. Cohen, Jonathan A. Cohen

Margo Panush Cohen is an American physician, scientist, and entrepreneur. She has been a Professor of Internal Medicine and Chief of Endocrinology and Metabolism at the Wayne State University School of Medicine and the University of Medicine and Dentistry of New Jersey. She is President and Chief Scientific Officer of Glycadia, and a founder of its subsidiary Exocell.

Education

Cohen earned a BS from the University of Michigan and an MD from the University of Michigan Medical School. She held an internship at Sinai Hospital in Detroit, Michigan and a residency at Detroit's Henry Ford Hospital. She was then awarded fellowships from the Public Health Service and the National Institutes of Health and pursued doctoral studies in biochemistry at Wayne State University. Moving with her family to Argentina, she completed her doctoral program.[1][2]

Career

Returning from Argentina, Cohen joined the faculty of Wayne State University School of Medicine as an Assistant Professor of Medicine, becoming Full Professor with tenure and head of Endocrinology and Metabolism at the Medical Center’s Detroit Receiving Hospital.[1] In 1982 she became Professor of Medicine and Head of the Division of Endocrinology and Metabolism at the University of Medicine and Dentistry of New Jersey. She received a Fulbright Scholarship in 1986 for a sabbatical in Israel at the Beilinson Hospital/University of Tel Aviv.[1]

Cohen founded Exocell in 1988 to develop diabetes-related diagnostic products, and subsequently established Glycadia to develop therapeutic products. The company received initial financing from venture funds and the Commonwealth of Pennsylvania. The first FDA-approved diagnostic product was Albuwell, a test that detects diabetic kidney disease, followed by other diagnostic products approved by the U.S. Food and Drug Administration (FDA) to monitor diabetes management and complications.[1][3] Cohen is the inventor and holder of twelve patents in the field of diabetes treatment.[4] Cohen has served as an editor medical and scientific journals, on study sections of the National Institutes of Health, and was twice appointed Chairman of the Board of Scientific Counselors for the National Institute of Dental Research at the National Institutes of Health.[5][6] She is currently the President and Chief Scientific Officer of Glycadia, where she continues research into diabetes and developing new patented technology.[7]

Research

Cohen has contributed to several areas in endocrine and diabetes research. While in graduate school, she uncovered the mechanism by which the anti-convulsant aminoglutethemide interferes with the production of adrenal steroids, leading to clinical use of the drug in hormone-dependent cancers.[8][9] In Argentina she studied the effects of diabetes, insulin and pituitary hormones on protein synthesis and vascular metabolism.[10][11] As a visiting scientist in England, she examined effects of diabetes on basement membranes.[12] In Israel, Cohen discovered the increased prevalence of diabetes in young Ethiopian immigrants and linked it to radical changes in dietary habits.[13][14] She has also researched immune factors diabetes[15] and the cause of kidney, eye and vascular complications tied to diabetes, uncovering the role of increased nonenzymatic glycation in their genesis and identifying abnormalities in the production of matrix components and in signaling pathways inhibition.[16][17][18][19][20][21] Cohen was elected a member of the American Society for Clinical Investigation in 1982 and is currently an emeritus member of the society.[22]

Publishing

Cohen has authored and edited numerous books in the areas of diabetes, endocrinology and metabolism. These include:

  1. Diabetes and Protein Glycosylation: Methods of Measurement and Biologic Relevance; Springer Verlag, New York(1986) ISBN 0-387-96297-2
  2. The Polyol Paradigm and Complications of Diabetes; Springer Verlag, New York (1987) ISBN 0-387-96418-5
  3. Special Topics in Endocrinology and Metabolism; Alan R. Liss, Inc., New York(1979) ISBN 0-8451-0700-3; (1980) ISBN 0-8451-0701-1; (1981) ISBN 0-8451-0702-X; (1982)ISBN 0-8451-0703-8; (1983) ISBN 0-8451-0704-6; (1984) ISBN 0-8451-0705-4; (1985) ISBN 0-8451-0706-2
  4. Endocrinology & Metabolism: Hormone Resistance and Endocrine Paradoxes;Springer Verlag, New York (1987) ISBN 0-387-96517-3
  5. Controversies in Diabetes and Pregnancy; Springer Verlag, New York (1988) ISBN 0-387-96622-6
  6. The Brain as an Endocrine Organ; Springer Verlag, New York(1989) ISBN 0-387-96644-7
  7. Diabetes and Autoimmunity; Springer Verlag, New York (1990) ISBN 0-387-96645-5
  8. Diabetes and Protein Glycation. Clinical and Pathophysiological Relevance;JC Press, Philadelphia(1996) ISBN 0-965-46540-3

Personal life

Cohen married her college boyfriend, Perry M. Cohen, an investment banker, and she is the mother of three sons: Michael H. Cohen, Daniel A. Cohen, and Jonathan A. Cohen.[1][23][24][25]

References

  1. ^ a b c d e Valerie Reitman (February 20, 1989). "A Doctor Gets Down To Business". Philadelphia Inquirer. {{cite news}}: Italic or bold markup not allowed in: |publisher= (help)
  2. ^ "Margo Cohen". Retrieved February 25, 2014.
  3. ^ "Brotherly Love, Cheese Steaks And Biomed?". Businessweek. March 3, 1991. Retrieved September 24, 2013. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)
  4. ^ "Margo P Cohen - Inventor". Retrieved September 24, 2013.
  5. ^ Richard Stone (May 21, 1993). "Dental Institute Report Has NIH Down in the Mouth" (PDF). Science. p. 1069. Retrieved September 24, 2013. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)
  6. ^ http://www.sciencedirect.com/science/journal/19315244/149
  7. ^ "Patent Application Titled "Long-Acting and Controlled Release Formulations of 2-[(3-Chlorophenyl) Amino] Phenylacetic Acid" Published Online". Diabetes Week. February 17, 2014. Retrieved March 19, 2014. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)
  8. ^ Cash, Ralph; Brough, A. Joseph; Margo, N.P.Cohen; Satoh, Paul S. (1967). "Aminoglutethimide as an inhibitor of adrenal steroidogenesis". J ClinEndocrinol & Metab. 27: 1239–1242.
  9. ^ Cohen, Margo P. (1968). "Aminoglutethimide inhibition of adrenal desmolase activity". Proc Soc Exper Biol & Med. 127: 1086–1090.
  10. ^ Margo P. Cohen and Virgilio G. Foglia."Aortic mucopolysaccharides in experimental diabetes." Diabetes 19:639-643, 1970
  11. ^ M.P. Cohen and L. Grinblat."Effect of diabetes on the activity of soluble factors required in ribosomal protein synthesis."Horm&Metab Res 4:249-253, 1972
  12. ^ Margo Cohen; et al. (May 1981). "Nonenzymatic Glycosylation of Basement Membranes" (PDF). Diabetes. Retrieved September 24, 2013. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)
  13. ^ Margo Cohen; et al. (June 1988). "High Prevalence of Diabetes in Young Adult Ethiopian Immigrants to Israel" (PDF). Diabetes. p. 824. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)
  14. ^ C.N. Hales, Fetal nitrition and adult diabetes. Scientific American, Jul-Aug, 1994 pp.53-54
  15. ^ Warren Leary (June 19, 1990). "Researchers closing in on a large scale test to screen for diabetes". New York Times. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)
  16. ^ Margo Cohen; et al. (October 8, 2001). "Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-bold beta1". Kidney International. Retrieved September 24, 2013. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)
  17. ^ Margo Cohen; et al. (November 2008). "Amelioration of Diabetes-Associated Abnormalities in the Vitreous Fluid by an Inhibitor of Albumin Glycation" (PDF). Investigative Ophthalmology & Visual Science. Retrieved September 24, 2013. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)
  18. ^ Margo P. Cohen, Elizabeth Shea, Van-Yu Wu. "Inhibiting low density lipoprotein glycation ameliorates increased cholesteryl synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats." Metabolism 59:658-663, 2010
  19. ^ Laurence Kennedy, Maria Pilar Solano, Luigi Meneghini, Margaret Lo, Margo P. Cohen. "Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes."Am J Nephrol 31:110-116, 2010
  20. ^ Cohen, Margo P.; Chen, Sheldon; et al. (2005). "Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy". Kidney Int. 68: 1554–1561.
  21. ^ Margo P. Cohen, Gregory T. Lautenslager et al. "Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and Collagen IV subchain production and the development of renal insufficiency." Amer J Physiology – Renal Physiology 292:F789-F795, 2007
  22. ^ "Margo Panush Cohen, MD PhD". Retrieved October 8, 2013.
  23. ^ Michael H. Cohen (2007). Healing at the Borderland of Medicine and Religion. University of North Carolina Press. p. xii. Retrieved September 24, 2013.
  24. ^ "Nancy Ann Jeffrey Weds Daniel Cohen". New York Times. August 18, 1991. Retrieved September 24, 2013. {{cite news}}: Italic or bold markup not allowed in: |publisher= (help)
  25. ^ "Perry M. Cohen obituary". Retrieved March 19, 2014.

Template:Persondata

Retrieved from "https://en.wikipedia.org/w/index.php?title=Margo_Cohen&oldid=705776390"